Optimum Investment Advisors Has $279,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Optimum Investment Advisors lessened its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 59.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,244 shares of the company's stock after selling 4,750 shares during the period. Optimum Investment Advisors' holdings in Novo Nordisk A/S were worth $279,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Novo Nordisk A/S in the fourth quarter worth about $404,910,000. Sustainable Growth Advisers LP raised its position in shares of Novo Nordisk A/S by 23.6% during the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after purchasing an additional 1,021,498 shares during the period. Amundi lifted its holdings in shares of Novo Nordisk A/S by 26.4% in the 4th quarter. Amundi now owns 3,311,456 shares of the company's stock worth $283,615,000 after purchasing an additional 692,567 shares during the last quarter. Parnassus Investments LLC acquired a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $51,072,000. Finally, DAVENPORT & Co LLC grew its stake in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company's stock worth $90,477,000 after buying an additional 451,641 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 2.2 %

Shares of Novo Nordisk A/S stock traded down $1.55 during trading on Thursday, hitting $70.18. The stock had a trading volume of 7,960,944 shares, compared to its average volume of 5,481,867. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $314.93 billion, a PE ratio of 21.33, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $69.78 and a 1 year high of $148.15. The stock has a 50 day simple moving average of $82.52 and a 200 day simple moving average of $99.54.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Analyst Upgrades and Downgrades

NVO has been the subject of several analyst reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.